All the Drug Class Drugs
Varicella Zoster Vaccines. Varicella Zoster Virus Vaccines 50 mcg/ 0.5 ml. 50 mcg/0.5 ml
Vials. Powder and susp. for IM inj.1/10 X 0.5 ml
Vaccination sched. consists of 2 doses of 0.5 mL each: an initial dose followed by a second dose 2 months later.
Prevent. of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in
adults 50 years of age or older and adults 18 years of age or older at incr. risk of HZ.
C/I: Hypersens.
Varicella Zoster Vaccines. Varicella virus live attenuated NLT 2000 PFU. PWDR (+ solv. for inject): 0.5 ml (1 dose).
S.C. in deltoid. 12 mths-12 yrs: 1 dose.
13 yrs and over: 2 doses with interval
of 6 wks (minimum) betw. doses. High
risk pts: additional doses may be reqd.
Not to be admin. intraderm. or
intravasc.
Active immunizat. against varicella in
healthy pts. only from 12 mths of age.
in individuals with severe humoral or cellular (primary or acquired) immunodef. such as:subjects with immunodefic. states with a total lymphocyte count less than 1,200 per mm3; subjects presenting other evidence of lack of cellular immune competence (e.g. leukaemias, lymphomas, blood dyscrasias, clinic. manifest HIV infect.); subjects on current or recent immunosuppressive ther. (including high doses of corticosteroids). Not contraindic. in individuals who are receiving topical or low-dose parenteral corticosteroids (e.g. for asthma prophylaxis or replacement ther.);
severe combined immunodefic.; agammaglobulinemia;
AIDS or symptom. HIV infect. or an age-specific CD4+ T-lymphocyte percentage in children below 12 months: CD4+ <25%; children between 12-35 months: CD4+ < 20%; children between 36-59 months: CD4+ < 15%.
*Hypersens. incl to neomycin. but a hist. of contact dermatitis to neomycin is not a contraindic.
*Subjects having shown signs of hypersens. after previous admin. of varicella vaccine.
*Pregn. In addit., pregn. should be avoided for 1 month following vaccin.
Varicella Zoster Vaccines. Varicella Zoster Virus Vaccines 19,400 PFU/0.65 ml. PRE-FILLED SYR. (PWDR + SOLV. for INJ.):
0.65 ml.
S.C. a single dose (0.65 ml), prefer.
in the deltoid region. Do not inject
intravascularly.
Prevention of herpes zoster (shingles) in
pts. 50 yrs of age and older.
C/I: Hypersens. to the product, to any of
the excip. (e.g., neomycin);
Primary/ acquired immunodef. states;
Immunosuppress. ther. (incl. high-dose
corticoster.), however, it is not C/I for use
in pts. who are receiv. topical/inhaled
corticoster. or low-dose syst. corticoster.
or in pts. who are receiv. corticosteroids
as replacem. ther. Active untreated tuberculosis; Pregn.
and should be avoided for 1 mnth foll.
vaccine.
